The market for arthroscopic devices has been witnessing a paradigm shift from conventional open surgeries to the minimally invasive ones, on the back of complications pertaining to the former.
Many governments around the world are taking initiatives associated with healthcare tourism via deals and packages, which include easier visa approvals, and post-operation follow-ups.
These factors will positively influence the market for arthroscopic devices globally. Revenues from the market are expected to exceed USD 1.7bn by 2022-end.
Hospitals are expected to remain the largest end-users of arthroscopic devices in the global market.
Most of the patients prefer hospitals for arthroscopic procedure over other healthcare settings such as orthopedic clinics, and ASCs.
This is mainly because hospitals procure medical products, consumables, and accessories in bulk quantity, engaging closely with manufacturers and suppliers, government agencies, and reimbursement authorities.
Among various products in the global arthroscopic devices market, arthroscopes are expected to remain the most lucrative, with sales anticipated to register an impressive expansion through 2022.
The number of arthroscopic procedures is witnessing a significant surge, owing to the rise in older population worldwide. In addition, requirement for accurate and early diagnosis of patient conditions have increased demand for cost-effective minimally-invasive procedures, such as arthroscopy.
These factors are expected to spur demand for arthroscopes over the forecast period.
The market in Asia-Pacific excluding Japan (APEJ) is poised to gain a significant traction over the forecast period, particularly in the region's developing economies such as China and India. Existence of better insurance schemes, favourable reimbursements, low taxation, increased sports activity and related injuries, and rise in purchasing power of population in the region are key drivers for growth of the market in APEJ.
Moreover the healthcare tourism in India and China is gaining popularity owing to a relatively lower expenditure requirement, and rising treatment success rates through use of technologically advanced systems.
This will further influence expansion of the arthroscopic devices market in APEJ. However, the markets in North America and Europe are expected to remain comparatively more lucrative, owing to presence of leading market players, and relatively higher healthcare tourism attraction.
Knee arthroscopy is expected to remain the largest application of arthroscopic devices, with revenues accounting for over one-third share of the market during 2017 to 2022.
Hip arthroscopy will stick to its position of being the second most lucrative application of arthroscopic devices. Between spine arthroscopy and shoulder and elbow arthroscopy, the former will account for larger revenues, whereas the latter will exhibit a higher CAGR through 2022.
High-volume commoditisation of arthroscopic devices, owing to their constant replacement, is creating a steady revenue stream for medical device manufacturers. Various technological advancements are having been witnessed in arthroscopic devices since recent past.
For instance, Zimmer Biomet introduced "Vanguard" in 2016, which revolutionized the total knee replacement procedure.
In addition, a slew of innovations in arthroscopy visualization systems, such as development of high, and ultra-high definition systems providing an enhanced video quality, has facilitated visualisation of patients' anatomy.
Lower risk of infections associated with the arthroscopy procedures, coupled with faster recovery time of patients and rapid results obtained by the procedures are expected to propel demand for arthroscopic devices.
Utilising standardized imaging systems, arthroscopy has taken a digital leap to customized operation theatres, which have integrated fluid management systems, power instruments, cameras, and endoscopes. This will further influence demand for arthroscopic devices in the years to come.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA